A pharmaceutical company is developing a new oral antibiotic. During preclinical studies, they observe that the drug undergoes extensive first-pass metabolism. Which of the following is the most common organ responsible for first-pass metabolism of orally administered drugs?

Explanation

## First-Pass Metabolism: Sites and Mechanisms **Key Point:** The liver is the most common and quantitatively most significant site of first-pass metabolism for orally administered drugs, accounting for the majority of presystemic elimination. ### Comparison of First-Pass Metabolism Sites | Organ | Enzyme System | Contribution to First-Pass | Clinical Significance | | --- | --- | --- | --- | | **Liver** | CYP450 (Phase I), Phase II enzymes (conjugation) | 70–90% of first-pass effect | Primary determinant of oral bioavailability | | Intestinal wall | CYP3A4, UDP-glucuronosyltransferase | 10–30% (variable) | Significant for some drugs (e.g., midazolam, cyclosporine) | | Stomach | Acid, pepsin, some oxidative enzymes | < 5% | Minimal; mainly drug degradation, not metabolism | | Kidney | Glomerular filtration, tubular secretion | Negligible for first-pass | Not a first-pass site; occurs after systemic absorption | ### Why Liver Dominates First-Pass Metabolism 1. **Anatomical position:** Oral drugs are absorbed from the GI tract and enter the portal circulation, which drains directly into the liver before reaching systemic circulation. 2. **Enzyme richness:** The liver contains the highest concentration of drug-metabolizing enzymes (CYP450 isoforms, Phase II enzymes). 3. **Metabolic capacity:** Hepatic blood flow (~1500 mL/min) and enzyme abundance make the liver the major site of drug elimination. **High-Yield:** Drugs with high hepatic extraction ratio (e.g., propranolol, nitroglycerin, morphine) undergo extensive first-pass metabolism and have low oral bioavailability. These drugs are given sublingually or transdermally to bypass first-pass effect. **Clinical Pearl:** The intestinal wall contributes 10–30% of first-pass metabolism for some drugs (especially CYP3A4 substrates like midazolam and tacrolimus), but the liver remains the dominant site. This is why grapefruit juice (CYP3A4 inhibitor) affects drug levels more predictably when hepatic metabolism is involved. **Mnemonic:** **LIVER FIRST** — **L**iver is the **I**nitial **V**ital **E**limination site; **R** = **F**irst-pass **I**s **R**apid **S**ystemic **T**reatment-limiting.